Shionogi buys its way into China with planned C&O acquisition
This article was originally published in Scrip
Executive Summary
Shionogi has announced plans to acquire the Singapore-listed Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) for a total of around S$219 million ($182.5 million), in a move aimed at strengthening its presence in the increasingly critical Chinese pharma market.